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CASE REPORT

Posterior reversible encephalopathy syndrome while
receiving irinotecan with fluorouracil and folinic acid
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ABSTRACT
Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome with seizures, headache,
altered mental status and visual disturbances. It is typically associated with posterior cerebral white matter oedema on
neuroimaging. There is an increasing number of cases of PRES reported with different chemotherapeutic protocols.
However, PRES is rarely reported in association with irinotecan, fluorouracil and folinic acid (FOLFIRI). We report a 28year-old female patient with a history of Stage IV gastric cancer who presented with abdominal pain and recurrent
vomiting that was thought to be related to a partial intestinal obstruction secondary to peritoneal metastasis. Eventually,
she was treated with FOLFIRI. A few hours after initiation of the fluorouracil infusion in the second cycle, she developed a
tonic-clonic seizure. MRI of the brain showed multiple bilateral T2 and flair hyperintense cortical and subcortical lesions
suggestive of PRES. Other causes of PRES were excluded, as well as brain metastasis. Unfortunately, the patient
developed septic shock and died a few days after her presentation.

BACKGROUND
Posterior reversible encephalopathy syndrome (PRES) is a
distinct clinical-radiographic syndrome that was first
described by Hinchey et al.1 PRES presents with seizures,
headache, altered mental status or visual disturbances,
associated with posterior cerebral white matter oedema on
neuroimaging.1,2 Even though PRES is a benign and
reversible condition,1,3 it can also can be fatal or lead to
permanent neurological disability.4 Thus, an early diagnosis of PRES is crucial to prevent complications.5 Chemotherapeutic agents are uncommonly recognized as risk
factors or causative agents for PRES.2 A toxic damage to
the vascular endothelium, blood brain barrier (BBB) dysfunction by cytotoxic effect and a possible modulation of
inflammatory cascades can lead to increased BBB permeability with resulting oedema.5–7 Treatment of PRES is
supportive by controlling blood pressure and stopping the
inciting factor.2,7 In this case report, a 28-year-old female
patient with a history of Stage IV gastric cancer developed
PRES while she was receiving chemotherapy. Other potential causes of her presentation as well as other causes of
PRES were excluded. Unfortunately, she developed septic
shock and died a few days afterward.

CASE SUMMARY
Clinical presentation
Our patient was a 28-year-old female individual with a
past medical history of benign essential hypertension and
Stage IV gastric cancer with peritoneal metastasis, for
which she had completed five cycles of docetaxel, cisplatin
and 5-flurouracil (DCF). CT scan of the abdomen and pelvis 3 weeks after the last cycle of DCF showed disease progression and worsening peritoneal metastasis.
Two weeks later, she presented to the emergency room
with abdominal pain and recurrent vomiting for the last
few days. On evaluation, she was in distress. Her temperature was 37.6°C, her heart rate was 106 beats min–1 and
her blood pressure was 139/87 mmHg. The abdomen was
slightly distended with mild tenderness to palpation in the
epigastric area. No rebound tenderness, guarding or rigidity were noted. CT scan of the abdomen and pelvis with
contrast showed a focal dilatation of proximal jejunal loops
suggestive of partial intestinal obstruction. The patient was
admitted for medical management of the intestinal
obstruction and surgical consultation.

© 2017 The Authors. Published by the British Institute of Radiology. This is an open access article under the terms of the Creative Commons Attribution
4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are
credited.

BJR|case reports

The patient was started on intravenous hydration and was kept
nil per os (NPO). The serum amylase and lipase levels were normal. The surgery team decided to continue with conservative
treatment owing to a high surgical risk and peritoneal metastasis. After a few days, the pain and vomiting improved.
The tumour board committee thought that the jejunal
obstruction was due to disease progression. They decided to start
irinotecan intravenously (i.v.) 180 mg m–2, folinic acid i.v.
400 mg m–2 and fluorouracil i.v. 400 mg m–2 as a bolus dose, followed by 2400 mg m–2 i.v. infusion over 46 h (FOLFIRI chemotherapy regimen).
The vomiting recurred after the initiation of chemotherapy and
was worse than before, which warranted keeping her as an inpatient. Multiple antiemetics were used to control her vomiting,
including metoclopramide, ondansetron, lorazepam and eventually an octreotide i.v. infusion.
The patient’s vomiting was fairly controlled with the octreotide
infusion and the above antiemetic regimen. The second cycle of
FOLFIRI was started 14 days after the first cycle with the same
doses. 4 hours after initiation of the fluorouracil infusion, she
developed a tonic-clonic seizure for 2 min, which was controlled
with 5 mg i.v. of diazepam.
The patient was haemodynamically stable after the seizure with
mild hypertension (157/87 mmHg). Her neurological examination was non-focal. The fluorouracil was stopped and phenytoin
i.v. 1000 mg was given.
INVESTIGATION
A brain MRI with contrast (Figure 1) was done. T1 (Figure 1a),
T2 (Figure 1b) and T2-flair (Figure 1c) showed multiple bilateral
T2 and flair hyperintense cortical and subcortical lesions in the
parietal and occipital lobes, as well as in the cerebellar hemispheres. Some lesions showed minimal enhancement. No
restriction was noted on diffusion-weighted images. There was
no significant surrounding oedema, intracranial haemorrhage,
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space-occupying lesions, hydrocephalus or midline shift. Brain
metastasis was less likely given the acuity of onset, the absence
of brain metastasis on previous brain MRI, the absence of
enhancing lesions at the gray-white matter junction and the
absence of distortion of the brain architecture. Her electrolyte
levels were unremarkable. An echocardiogram with bubble study
(was done 3 days after the seizure) did not show any vegetations
or intracardiac shunts. These findings were consistent with
PRES.
Follow-up
Unfortunately, the patient developed Klebsiella bacteremia and
septic shock 2 days after the seizure and was transferred to the
intensive care unit. She deteriorated despite all efforts, and died
after 7 days.
DISCUSSION
PRES is a clinical-radiographic syndrome of seizures, headache,
altered mental status and visual disturbances associated with
posterior cerebral white matter oedema on neuroimaging. PRES
was first described by Hinchey et al.1 Interestingly, this syndrome is not always reversible, and the cerebral oedema can
involve any part of the brain. Therefore, the name is not
completely satisfactory.
The exact incidence of PRES is unknown. It affects all age groups
and is more common in female individuals.2–4 Tam et al5 specified particular risk factors for PRES, including significant fluid
overload (>10% of baseline weight), increased blood pressure
(>25% of baseline) and creatinine > 1.8 mg dl–1. Any of these
risk factors should promote the use of early neuroimaging to
evaluate any unexplained neurological change.5
Chemotherapy-associated PRES is uncommon, even though
there is an increasing number of reported cases.2,5–8 How et al 2
included 70 cases in their systematic review on chemotherapyassociated PRES. Most of the cases presented within the first
week of chemotherapy. The most commonly encountered

Figure 1. Brain MRI with contrast. (a) T1 sequence, (b) T2 sequence, (c) T2-flair sequence. These sequences show multiple bilateral T2
and flair hyperintense cortical and subcortical lesions in the parietal and occipital lobes, as well as in the cerebellar hemispheres.
Some lesions showed minimal enhancement. No significant surrounding oedema, intracranial haemorrhage, space-occupying
lesions, hydrocephalus or midline shift are seen.
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Table 1. Reported cases of PRES with FOLFIRI chemotherapy

Case/primary
malignancy

Patient’s age/
gender

Chemotherapy
regimen

Presenting
symptom

Onset (days after
chemotherapy)

Involved brain
areas on
neuroimaging

Plavetić et al6/
Stage IV colorectal
cancer

45-year-old/ female

FOLFIRI

Headache and tonic-clonic seizures

5 days

The occipital and
posterior parietal
lobes

Allen et al7/ Stage
IV colorectal cancer

52-year-old/ male

FOLFIRI/bevacizumab

Headache and bilateral cortical
blindness

14 days

The occipital and
posterior parietal
lobes

Abughanimeh et al
(our case)/Stage
IV gastric cancer

28-year-old/ female

FOLFIRI

Seizure

First day (2 h after
the fluorouracil
infusion)

Cortical and subcortical lesions in
the parietal and
occipital lobes.
Cerebellar hemispheres

chemotherapeutic agents were platinum-based agents (cisplatin,
carboplatin and oxaliplatin—
—30 cases), daunorubicin (24 cases)
and vinca alkaloids (vincristine, vinorelbine, vinflunine,
vinblastine and vindesine—
—21 cases). There were 13 cases
associated with 5-fluorouracil and 1 case associated with irinotecan. None of the cases were associated with FOLFIRI. To the
best of our knowledge, this case is the second reported case of
PRES after FOLFIRI treatment alone. Additionally, our case is
the first case that includes gastric cancer [Table 1].
There is no clear explanation for the pathophysiology of chemotherapy-associated PRES. Toxic damage to the vascular endothelium and BBB dysfunction due to cytotoxic medications could
explain part of it. Additionally, cytotoxic medications can
increase tumour cell recognition, which stimulates an inflammatory cascade that can lead to increased BBB permeability and
axonal swelling that leads to vasogenic oedema.5–7
In general, the most common neuroimaging finding in PRES is
oedema of the white matter in the posterior portions of the cerebral hemispheres, especially in the bilateral parieto–occipital
regions.1 However, any part of the brain could be involved,
including the brain stem, cerebellum or basal ganglia.1 In chemotherapy-associated PRES, involvement of the temporal and
frontal lobes is possible as well.2 It has been noted that involvement of the occipital lobes increases the risk of having a seizure.9
Finally, PRES is usually a benign condition. Many cases seem to
be fully reversible within days to weeks after removal of the
inciting factor and with good blood pressure control.1,3

However, PRES can also be fatal or lead to permanent
neurological disability.4
CONCLUSION
Chemotherapy-associated PRES is uncommon, but has been
reported. It shares many clinical and radiological characteristics
with other cases of PRES. Early diagnosis of PRES as well as recognition of risk factors is important to prevent complications.
LEARNING POINTS
1. PRES is a clinical-radiographic syndrome with a variety
of clinical features and characteristics on neuroimaging.
2. The most common neuroimaging finding with PRES is
oedema of the white matter in the posterior portions of
the cerebral hemispheres, especially in the bilateral
parieto–occipital lobes.
3. Risk factors for PRES include significant fluid overload,
worsening hypertension and impaired kidney function.
4. Chemotherapy-associated PRES is uncommon but has
been reported.
CONSENT
Written informed consent for the case to be published
(including images, case history and data) was obtained from the
patient(s) for publication of this case report, including
accompanying images.
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